Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: Ann Intern Med. 2013 Jun 18;158(12):853–860. doi: 10.7326/0003-4819-158-12-201306180-00002

Table 4.

Threshold Analyses of Scenarios in Which the QALE of AS if Equal to or Better Than That of WW*

Model Parameter AS Base Case Threshold Value at Which AS QALE is Equal to or BETTER Than WW QALE
Men aged 65 y
    HR for prostate cancer-specific death for treatment vs. AS 1.85 ≥7.71
    Lifetime probability of being treated on AS, % 78 ≤63
    Utility of AS at which AS if favored over WW 0.83 ≥0.87
Men aged 75 y
    HR for prostate cancer-specific death for treatment vs. AS 1.85 ≥4.30
    Lifetime probability of being treated on AS, % 61 ≤42
    Utility of AS at which AS if favored over WW 0.83 ≥0.84

AS = active surveillance; HR = hazard ratio; QALE = quality-adjusted life expectancy; WW = watchful waiting.

*

WW remains less expensive than AS under every reasonable scenario modeled.